REGN logo Regeneron Pharmaceuticals +
Regeneron Pharmaceuticals
+

Regeneron Pharmaceuticals (REGN) Business News

Track Regeneron Pharmaceuticals in real time with a live news feed covering Regeneron Pharmaceuticals stock news, official press releases, company announcements, and an archive of historical Regeneron Pharmaceuticals news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Regeneron: Is The Market Undervaluing Its Growth Potential

Seeking Alpha

9:45 AM | Thursday | Oct 22, 2026

news photo
Loading...

At the end of October, Regeneron Pharmaceuticals, Inc. will report its results for Q3. As a reminder, REGN's Q2 revenue rose 18.8% quarter-on-quarter and 16.6% YoY to $4.
29 billion, primarily due to the strong performance of Dupixent. On October 12, Regeneron reported positive Phase 3 OPTIMA results, demonstrating sustained Pasatru efficacy in reducing new HO lesions and disease flare-ups in people with FOP.

Read full article redirect
9:45 AM | Thursday | Oct 22, 2026

Regeneron: Is The Market Undervaluing Its Growth Potential

Seeking Alpha

At the end of October, Regeneron Pharmaceuticals, Inc. will report its results for Q3. As a reminder, REGN's Q2 revenue rose 18.8% quarter-on-quarter and 16.6% YoY to $4.
29 billion, primarily due to the strong performance of Dupixent. On October 12, Regeneron reported positive Phase 3 OPTIMA results, demonstrating sustained Pasatru efficacy in reducing new HO lesions and disease flare-ups in people with FOP.

Read full article arrow
News Thumbnail
10:24 AM | Monday | Oct 19, 2026

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market

The Motley Fool

Regeneron's leading weight-loss candidate could offer patients an option with fewer side effects. The company has another investigational weight-loss medicine designed to help preserve lean muscle mass.

Read full article arrow
News Thumbnail
4:48 AM | Monday | Oct 19, 2026

Frank Rimerman Advisors LLC Acquires 876 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Defense World

Frank Rimerman Advisors LLC lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 153.7% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 1,446 shares of the biopharmaceutical company's stock after purchasing an additional 876 shares during the quarter. Frank Rimerman Advisors LLC's holdings

Read full article arrow
News Thumbnail
4:09 AM | Sunday | Oct 18, 2026

Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Insider Sells $3,204,386.90 in Stock

Defense World

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) insider Andrew Murphy sold 4,147 shares of the stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90.
Following the transaction, the insider owned 47,833 shares in the company, valued at

Read full article arrow
News Thumbnail
2:03 AM | Sunday | Oct 18, 2026

Regeneron’s Murphy sells $3.2 million in stock under plan (NASDAQ: REGN)

Defense World

What happened Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) said Co-Chief Scientific Officer Andrew J. Murphy sold 4,147 shares on 10/14/2026. The shares sold for $753.76 to $781.
47 each and brought in about $3.20 million, according to the Form 4. The filing says the trades were made under a Rule 10b5-1 trading plan. The same filing shows

Read full article arrow
News Thumbnail
3:24 PM | Saturday | Oct 17, 2026

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

The Motley Fool

Regeneron's revenue is growing at a good clip despite declining Eylea sales. Dupixent is the main reason behind recent strong financial results.

Read full article arrow
News Thumbnail
7:00 AM | Friday | Oct 16, 2026

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

GlobeNewsWire

Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment

Read full article arrow
News Thumbnail
4:44 AM | Friday | Oct 16, 2026

2,281 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by First Citizens Bank & Trust Co.

Defense World

First Citizens Bank and Trust Co. bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,281 shares of the biopharmaceutical company's stock, valued at approximately $1,730,000. Other

Read full article arrow
News Thumbnail
8:10 AM | Thursday | Oct 15, 2026

Here Are Thursday’s Top Wall Street Analyst Research Calls: AngloGold Ashanti, Bank of America, Cirrus Logic, Crocs, Diamondback Energy, Devon Energy, Netflix, PayPal, Spotify Technolgy , and More

247 Wallst

Hotter-than-expected inflation sent stocks and crypto tumbling Wednesday, and Wall Street analysts wasted no time reshuffling their targets on Thursday, with major calls hitting Bank of America, Netflix, PayPal, and several energy giants all at once.

Read full article arrow
News Thumbnail
9:56 AM | Wednesday | Oct 14, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks Investment Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Read full article arrow
News Thumbnail